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Abstract
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM
was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition
of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to
develop a new risk stratification system. We included 1996 patients, and using stepwise selection and multivariable
analysis, we identified three independent factors predicting progression risk at 2 years: serum M-protein >2 g/dL (HR:
2.1), involved to uninvolved free light-chain ratio >20 (HR: 2.7), and marrow plasma cell infiltration >20% (HR: 2.4). This
translates into 3 categories with increasing 2-year progression risk: 6% for low risk (38%; no risk factors, HR: 1); 18% for
intermediate risk (33%; 1 factor; HR: 3.0), and 44% for high risk (29%; 2–3 factors). Addition of cytogenetic abnormalities
(t(4;14), t(14;16), +1q, and/or del13q) allowed separation into 4 groups (low risk with 0, low intermediate risk with 1,
intermediate risk with 2, and high risk with ≥3 risk factors) with 6, 23, 46, and 63% risk of progression in 2 years,
respectively. The 2/20/20 risk stratification model can be easily implemented to identify high-risk SMM for clinical
research and routine practice and will be widely applicable.
Introduction
Smoldering multiple myeloma (SMM) represents a
transitional stage between monoclonal gammopathy of
undetermined significance (MGUS) and active multiple
myeloma (MM)1,2. Before International Myeloma Work-
ing Group (IMWG) revised the MM diagnostic criteria,
SMM was defined by the presence of either a serum
monoclonal protein of ≥3 g/dL (or ≥500mg/24 h in urine
or both) and/or ≥10% bone marrow plasma cells (BMPCs)
without evidence of any CRAB symptoms (hypercalcemia,
renal impairment, anemia, or lytic bone lesions). SMM is
a heterogeneous disease with a risk of progression to MM
of 10% per year during the first 5 years following diag-
nosis, decreasing to 3% per year over the subsequent 5
years, and 1% per year after the 10 years of diagnosis3. The
Mayo Clinic and the Spanish Group had previously cre-
ated different risk stratification models that can identify
SMM patients with a 2-year risk of progression to MM of
≥50%. The Mayo Clinic model included M-protein (≥3 g/dL),
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BMPCs infiltration (≥10%), and the ratio of serum free
light chain (sFLC) (≥8 or <0.125) to categorize patients
into three subgroups, with a 52% risk of progression in 2
years for those presenting with all three risk factors4. The
Spanish model used the presence of ≥95% clonal plasma
cells among all BMPCs by immunophenotyping and the
presence of immune paresis and identifies a subgroup of
patients having both features with a 50% risk of pro-
gression at 2 years5.
The standard of care for SMM, irrespective of the risk
status of the patients, has been observation. However,
there are two randomized studies confirming the benefit
of early treatment in reducing the risk of progression to
MM. The Spanish Myeloma Group conducted the first
phase III trial in high-risk SMM, comparing lenalidomide
plus dexamethasone (Ld) versus observation, and Ld sig-
nificantly delayed the progression to MM and patients
lived longer (overall survival (OS))6. The Eastern Coop-
erative Oncology Group (ECOG) group has also reported
a significant benefit for the early treatment with single-
agent lenalidomide versus observation in SMM7.
Although the Spanish trial did not lead to a change in
the standard of care, it encouraged the IMWG to revise
the criteria for the definition of SMM and MM to identify
a subset of SMM with a 2-year risk of progression of
approximately 80% who were then categorized as MM.
The identification of this subgroup is based on the pre-
sence of any one of these biomarkers: BMPCs ≥60% or
involved/uninvolved sFLC ratio ≥100, and presence of >1
focal lesion on magnetic resonance imaging, in patients
having bone marrow with at least 10% of clonal BMPC
infiltration. This led to a paradigm shift as these patients
were then regarded as having myeloma and were offered
therapy8.
Other groups, in parallel, also created different models
to identify SMM patients with a progression risk at 2 years
of 50% using different features like positive uptake on
positron emission tomography–computed tomography
(PET-CT), type of M-protein, cytogenetic abnormalities,
increase in serum M-protein and decrease in hemoglobin
count over time, presence of Bence Jones proteinuria, or
genetic signatures, among others9–14. At the same time,
many clinical trials are ongoing in high-risk SMM
according to different risk models, and all these devel-
opments brought to the fore two issues: (i) the hetero-
geneity of the different risk models developed using rather
small series of SMM patients and (ii) the real impact of
the revised SMM definition. This forms the basis of the
current study.
We studied a large cohort of SMM patients to identify
factors that predicted progression to MM with the goal of
developing an easy risk score to predict the 2-year pro-
gression risk. The factors identified were M-protein (>2 g/
dL), BMPCs infiltration (>20%), and the ratio of involved
versus uninvolved sFLC (>20). In addition, we have also
created a risk score that accounts for the entire range of
the variable measurements, which can be used to provide
a more individualized 2-year risk of progression for every
SMM patient.
Patients and methods
Patients with SMM diagnosed after January 2004 were
included in this retrospective medical chart review from
participating IMWG sites globally. The SMM definition
required to be included in the study was based on the
2014 IMWG criteria8. Patients included in this analysis
required baseline data from diagnosis (+/−3 months), no
progression to MM or other plasma cell disorders within
6 months from diagnosis, a minimum follow-up of 1 year,
and should not have been included in any therapeutic
trial.
Trained staff collected data from the patient medical
charts in three case report forms: (i) patient registration
and demographics form, (ii) diagnosis and baseline
assessment form, and (iii) 12-month assessment form.
The Institutional Review Board at each site approved the
study. The study was conducted in accordance with the
Declaration of Helsinki and the International Council for
Harmonisation Guidelines.
The primary objective was to develop a risk stratifica-
tion model that will identify SMM patients who have high
risk of progression to MM or other plasma cell disorders
(50% progression risk within the first 2 years from diag-
nosis) based on the 2014 IMWG criteria for definition of
both SMM and MM.
Time to progression (TTP) to MM or amyloidosis was
the primary end point and was defined as the time elapsed
between diagnosis of SMM and when the patient
experienced progressive disease. All patients who did not
progress at the time of last follow-up were censored in the
TTP analysis. A secondary objective was to create a risk
scoring tool that would allow individualized estimate of
risk at various time points from diagnosis.
Statistical methods
Due to the nature of the study, no formal hypothesis
was used to calculate the sample size. We summarized
categorical variables as proportions and continuous vari-
ables as medians (range). Univariate Cox regressions were
run for each factor to assess an initial relationship
between a factor and progression to MM or related dis-
orders. For each factor where p ≤ 0.25, optimal cut points
were identified using Youden’s Index. Receiver operating
characteristic (ROC) curves were generated, with the cut-
off maximizing both sensitivity and specificity deter-
mined. Sensitivity and specificity were reported for these
optimal cut points. Interaction term between candidate
variables were included in the model selection if candidate
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variables with correlations satisfy the above criteria. Using
the optimal cut points, a stepwise regression analysis was
used to determine predictive variables using a required
selection stay criterion of 0.001. A random forest algo-
rithm consisting of an ensemble of decisions trees15 cre-
ated using the random Forest package was used to
confirm variable selection16. Important prognostic vari-
ables for predicting probability of progression at 2 years
were identified and ranked based on the percentage
change in mean squared error. Similar methods were used
to identify the most significant cytogenetic abnormalities
associated with progression to MM in patients with
available information.
Patients were categorized based on the number of risk
categories present and Cox proportional hazard regres-
sion models were used to calculate hazard ratios (HRs)
and 95% confidence intervals (CIs). Kaplan–Meier curves
were used to illustrate TTP across the number of risk
categories present.
A risk score was developed to elucidate the potential
strength of individual relationships between each of the
previously defined variables based on the method descri-
bed by Sullivan et al.17. Variables were categorized based
on clinically relevant as well as spline functions to
establish the general trends in the risk of progression with
increasing laboratory values. Scores for each risk factor
were assigned relative weights of each coefficient in the
multivariable regression model. Predicted risk of pro-
gression were summarized based on this scoring tool.
Analyses were conducted in SAS version 9.4 (The SAS
Institute, Cary, NC) and R Core Team (2018).
Results
Patient characteristics
One thousand nine hundred and ninety-six SMM
patients from 75 centers in 23 countries were included.
Baseline characteristics are in Table 1. The median age at
diagnosis was 64 years (interquartile range (IQR): 56–72).
The median serum M-component and BMPC infiltration
were 1.8 g/dL (IQR: 1.1–2.6) and 15% (IQR: 12–25),
respectively. Concerning cytogenetic information (avail-
able in 689 patients), trisomies and del13q/monosomy 13
were the most frequent abnormalities (31.4% and 28.4%,
respectively). 1q gain was reported in 25.4% and t(4;14)
and del(17p/monosomy 17) in 10.2% and 5.4%,
respectively.
Survival outcomes
The median follow-up from diagnosis was 3.0 years
(IQR 1.6–5.1). At the data cut-off, 815 (41%) patients had
progressed to MM or a related disorder. The median TTP
for the entire cohort was 6.4 years (95% CI 6.0–7.2); the 2-,
5-, and 10-year risk of progression were 22, 42, and 64%,
respectively (Fig. 1). The estimated 5- and 10-year OS for
the entire cohort from SMM diagnosis was 93.8%
(92.0–95.2) and 88.3% (84.8–91.1), respectively.
Risk factors for progression and stratification model
The factors initially included in the univariate analysis
for predicting progression risk at 2 years from the diag-
nosis are shown in Table 2 indicating those included in
the model because of their capacity for predicting risk of
progression to MM at 2 years (p value ≤ 0.25).
From among these, the stepwise model selection and
random forest algorithm identified serum M-protein
concentration, involved to uninvolved sFLC ratio, and
BMPC percentage as the most relevant factors predicting
progression to MM, and based on Youden’s Index in the
ROC analyses, the optimal cut-offs for the risk factors
were 1.9 g/dL for serum M-protein (specificity 60% and
sensitivity 71%), 19.3 for the involved to uninvolved sFLC
ratio (specificity 79% and sensitivity 55%), and 16.4% for
the BMPC infiltration (specificity 55% and sensitivity 75%)
as shown in Table 3. For convenience and simplicity, we





Age (years), median (range) 0 64 (56–72)
Gender (Male), % 0 978 (49%)
Hemoglobin (g/dL) 54 12.9 (11.8–13.8)
Creatinine (mg/dL) 136 0.88 (0.71–1.04)
Calcium (mg/dL) 172 9.3 (9–9.7)
Albumin (g/dL) 179 4 (3.7–4.3)
Beta-2 microglobulin (mg/dL) 357 2.3 (1.8–3)
Serum M-protein (g/dL) 0 1.8 (1.1–2.6)









Immunoparesisa 235 992 (56.3%)
Urine M-spike (mg/24 h) 792 0 (0–30)
BMPCb, higher of biopsy and
aspirate %
0 15 (12–25)
aImmunoparesis was defined as reduction in one or more of the uninvolved
immunoglobulin level below normal range.
bBone marrow plasma cell percentage.
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Fig. 1 Probability of progression over time in the full study cohort (n= 1996). The median time to progression for the entire cohort was 6.4
years (95% CI 6.0–7.2); the 2-, 5-, and 10-year risk of progression were 22, 42, and 64%, respectively.
Table 2 Identification of factors for risk stratification model.
p value Candidate factors (p value <0.25) Hazard ratio (95% CI)
Age (per 10 years) 0.034 Yes 1.09 (1.01, 1.19)
Female sex 0.4552 No 0.93 (0.77, 1.13)
Hemoglobin (g/dL) <0.0001 Yes 0.87 (0.82, 0.93)
Creatinine (mg/dL) 0.1192 Yes 1.2 (0.96, 1.5)
Calcium (mg/dL) 0.6844 No 0.98 (0.9, 1.07)
Albumin (g/dL) 0.0786 Yes 0.84 (0.68, 1.02)
Serum M-protein (g/dL) <0.0001 Yes 1.09 (1.06, 1.12)
Beta-2 microglobulin (mg/dL) <0.0001 Yes 1.21 (1.14, 1.29)
Absolute difference Kappa–Lambda (mg/dL), per 100 <0.0001 Yes 1.03 (1.01, 1.04)
Involved to uninvolved sFLC ratio, per 100 <0.0001 Yes 1.1 (1.06, 1.13)
Heavy-chain type (IgG versus IgM) 0.5003 No 0.92 (0.73, 1.17)
Heavy-chain type (IgG versus IgA) 0.3336 No 0.92 (0.78, 1.09)
Light-chain type (Kappa versus Lambda) 0.0611 Yes 0.83 (0.68, 1.01)
Immunofixation 0.9641 No n/a
Immunoparesisa <0.0001 Yes 1.53 (1.24, 1.89)
Urine M-spike (mg/24 h), per 1000 0.163 Yes 1.05 (0.98, 1.14)
BMPCb %, per 10 <0.0001 Yes 1.44 (1.36, 1.52)
n/a not applicable.
aImmunoparesis was defined as reduction in one or more of the uninvolved immunoglobulin level below normal range.
bBone marrow plasma cell percentage
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decided to use 2 g/dL, 20%, and 20% as cut-off levels for
these factors. Using these cut points, multivariable ana-
lysis identified the presence of serum M-protein >2 g/dL
as an independent prognostic factor predicting high risk
of progression to MM (HR: 2.07, 95% CI: 1.62–2.65),
together with involved to uninvolved sFLC ratio >20 (HR:
2.66, 95% CI: 2.09–3.38) and BMPC infiltration >20%
(HR: 2.39, 95% CI: 1.87–3.05).
We then proceeded to create a risk stratification model
including 1363 patients in whom all three factors were
available: five hundred and twenty-two patients (38%) did
not present any of the factors (reference group) with a risk
of progression at 2 years of 6% (the low-risk group); 1 out
of the 3 factors was identified in 445 patients (33%) with a
18% risk of progression to MM at 2 years (HR: 2.99, 95%
CI: 1.97–4.54) (the intermediate-risk group); and the
high-risk group defined by the presence of 2 or 3 risk
factors included 396 patients (29%) with a 44% progres-
sion risk at 2 years (HR: 9.02, 95% CI: 6.15–13.2) (Fig. 2a).
Of the 396 patients included in the high-risk group, 92
presented with the 3 risk factors and had a slightly higher
risk of progression to MM (Fig. 2b).
We explored the added value of the presence of any
cytogenetic abnormalities to the 2/20/20 risk model if all
factors were available (689 patients). The stepwise model
selection identified the presence of t(4;14), t(14;16), +1q,
and del13q/monosomy 13 by fluorescence in situ hybri-
dization (FISH) as the most relevant ones. This model
defined four groups of SMM patients with different pro-
gression risk at 2 years (Fig. 3): low risk with a progression
risk at 2 years of 6% (n= 225; 33%) and defined by the
presence of none of the factors; low–intermediate (n=
224; 33%) if one factor was present and the progression
risk at 2 years was 23% (HR: 4.16, 95% CI: 2.26–7.67);
intermediate risk (n= 177; 26%) defined by the presence
of 2 factors and risk of progression at 2 years of 46% (HR:
9.82, 95% CI: 5.46–17.7); and the high risk (n= 63; 9%)
with a progression risk at 2 years of 63% (HR: 15.5, 95%
CI: 8.23–29.0) if ≥3 of the factors were present.
Scoring tool to predict risk of progression at 2 years
Based on the univariate and multivariate analysis pre-
viously conducted, the three risk factors (serum M-pro-
tein, involved to uninvolved sFLC ratio, and BMPC
infiltration) together with the cytogenetic abnormalities
were included in a logistic regression model for creating a
scoring tool to provide a more individualized assessment
of risk. This approach allowed us to utilize the variables
along the entire range of values instead of using single cut
points. Six hundred and eighty-nine patients were inclu-
ded and Tables 4 and 5 present the score for each risk
factor and the predicted risk according to individual risk
scores. Patients with total risk score between 0 and 4 had
a 2-year progression risk of 3.8% (reference group). The
risk was 26% (HR: 7.56, 95% CI: 3.77–15.2) for patients
with a total score between 5 and 8, and for those with a
score between 9 and 12, the risk of progression at 2 years
was 51% (HR: 17.3, 95% CI: 8.63–34.8). When the score
was >12, the 2-year progression risk was 73% (HR: 31.9,
95% CI: 15.4–66.3) (Fig. 4).
Discussion
The treatment paradigms for myeloma has evolved
rapidly in the past decade with introduction of new
therapies, leading to improved survival18,19. The mostly
incurable nature of MM and a better understanding of the
disease biology coupled with the prolonged precursor
phase has inevitably directed our attention to developing
strategies for prevention or early intervention with the
goal of delaying onset of active disease or potentially
eradicating the clone20,21. The redefinition of active
myeloma was a first step in early intervention, with
treatment initiation not solely based on CRAB criteria.
The current study fills an important gap in terms of a risk
stratification approach for the newly defined SMM that
will allow us to design future clinical trials. We present
here a simple risk stratification model that can be applied
across the globe using easily available data to identify a
subgroup of SMM patients with 50% progression risk at 2
years, defined by the presence of two or three factors
Table 3 Receiver operating characteristic (ROC) curves
with area under the curve (AUC) analysis to identify
optimal cut-offs for continuous risk factors (identified
from Table 2) with respect to progression to MM within
2 years.
Cut point Specificity (%) Sensitivity (%)
Age (per 10 years) 57 28 80.6
Hemoglobin (g/dL) 13.3 39.9 73.3
Creatinine (mg/dL) 0.81 42.9 66
Albumin (g/dL) 4.09 46.4 64









sFLC ratio, per 100
19.3 78.7 54.7
Urine M-spike (mg/24 h),
per 1000
75 83.1 29.8
BMPC, higher of biopsy
and aspirate %
16.4 58.1 71.8
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Fig. 2 Risk of progression at 2 years based on presence or absence of risk factors in patients with smoldering multiple myeloma. a
Probability of progression at 2 years in the three different subgroups of patients according to the model 2/20/20. Patients with no risk factors (low-risk
group) had a risk of progression at 2 years of 6%, those with one factor (intermediate-risk group) had a risk of progression of 18% at 2 years, and those
with ≥2 factors (high-risk group) had a 44% progression risk at 2 years. b Probability of progression at 2 years according to the model 2/20/20 with
separation of high-risk group based on presence of 2 or 3 risk factors. Of the 396 patients included in the high-risk group, 92 presented with the three
risk factors and had a slightly higher risk of progression to MM.
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among M-protein >2 g/dL, BMPCs infiltration >20%, or
the ratio of involved to uninvolved sFLC >20. In this
study, we used 2-year progression as the end point in
order to maintain the approach used in the previous
models but now excluding the ultrahigh risk patients with
≥80% risk of progression at 2 years who are essentially
active M by current definition. This group represents a
relevant population for early intervention and inclusion in
trials in order to either prevent the MM development or
potentially cure the disease.
The updated IMWG definition segregated from the
classical SMM definition those patients with an imminent
risk of progression to MM; now considered as MM. This
subset of patients could potentially overestimate the
progression risk in the classical SMM series and should
therefore be excluded from the SMM risk stratification
models. The Mayo Clinic group recently examined their
cohort of SMM patients by removing those with MM
according to the 2014 IMWG criteria, and they identified
SMM at 50% risk of progression at 2 years based on M-
protein (>2 g/dL), BMPC infiltration (>20%), and the ratio
of involved to uninvolved sFLC (>20)22. Importantly, this
international database of nearly 2000 SMM patients
confirmed the Mayo Clinic 2/20/20 model, providing
robust validation for this new categorization of SMM
patients. In addition, the model is based on three features
easily available at most centers. Moreover, a subanalysis
conducted in a subset of patients with FISH information
showed that the presence of any one of the cytogenetic
abnormalities such as t(4;14), t(14;16), +1q, or del13q/
monosomy 13 was an additional predictor of progression
in this study. This is in line with a previous observation
from the Mayo Clinic study that identified the presence of
t(4;14), del17p), and/or hyperdiploidy as predictors of
progression10. Altogether these data reinforce the concept
that the genomic information such as mutations and
translocation affecting MYC may contribute to refine the
model, but this will require prospective validation in other
studies23.
Different investigators have defined alternative models
to evaluate the risk of progression from SMM to MM.
Most have been based on measurements of tumor bulk:
size of M-spike, sFLCs, type of immunoglobulin IgA
versus IgG, proportion of clonal plasma cells >95% of
aberrant cells, circulating plasma cells, or immune paresis.
These models are useful and have driven the clinical
research so far, being validated in clinical trials. However,
new models have emerged based on relatively small series
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Fig. 3 Probability of progression at 2 years in the four different subgroups of patients according to the model 2/20/20 plus cytogenetic
abnormalities (t(4;14), t(14;16), +1q, and/or del13q/monosomy 13). This model defined four groups of SMM patients: low risk with none of the
factors had a progression risk at 2 years of 6%, low–intermediate with one factor present had a progression risk at 2 years of 23%, intermediate risk
with the presence of 2 factors had a risk of progression at 2 years of 37%, and the high risk with ≥3 of the factors had a progression risk at 2 years
of 63%.
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of patients utilizing new imaging assessments like PET-
CT, genetic signatures, Bence Jones proteinuria, or
dynamic models such as the evolution of the M-
component and the decrease of hemoglobin, among
others. Although many of them identify SMM patients
with ≥50% risk of progression to MM within the first 2
years since diagnosis, in clinical practice, physicians are
frequently confused about what model to use to define the
risk of progression in SMM; moreover, many ongoing
clinical trials in SMM use different inclusion criteria,
which may be a confounding factor upon analyzing the
efficacy of new drugs/combinations in this setting. Taken
together, this model derived from an international SMM
population with commonly available and reproducible
biomarkers could be employed as a standard in registra-
tion trials as well as routine clinical practice.
The phase 3 trial conducted by the ECOG group eval-
uating single-agent lenalidomide versus observation in
SMM patients showed a significant benefit in progression-
free survival for the high-risk subset defined as in the
current study using the 2/20/20 model7. Moreover, the
same group decided to amend their new phase 3 trial
comparing Ld versus Ld plus daratumumab in high-risk
SMM in order to introduce the 2/20/20 model as inclu-
sion criteria. The ASCENT trial conducted by the
Table 4 Logistic regression equation to develop the risk
score predicting progression risk at 2 years.
Risk factor Coefficient Odds ratio (95% CI) p value Score
FLC IU
0–10 (reference) – – – 0
>10–25 0.69 1.99 (1.15, 3.45) 0.014 2
>25–40 0.96 2.61 (1.36, 4.99) 0.004 3
>40 1.56 4.73 (2.88, 7.77) <0.0001 5
M-protein
0–1.5 (reference) – – – 0
>1.5–3 0.95 2.59 (1.56, 4.31) 0.0002 3
>3 1.3 3.65 (2.02, 6.61) <0.0001 4
BMPC
0–15 (reference) – – – 0
>15–20 0.57 1.77 (1.03, 3.06) 0.04 2
>20–30 1.01 2.74 (1.6, 4.68) 0.0002 3
>30–40 1.57 4.82 (2.5, 9.28) <0.0001 5
>40 2 7.42 (3.23, 17.02) <0.0001 6
FISH abnormality 0.83 2.28 (1.53, 3.42) <0.0001 2
FLC IU involved to uninvolved serum-free light chain ratio.
Table 5 Predictive values of risk score tool.
Total risk score Predicted risk at 2 years based on Actual (% with 2-year progression) Predictive value
Risk score Full regression model Positive Negative
0 3.2 3.3 1 (1.3%) 25.8 n/a
2 6.2 6.1 3 (5.4%) 29.1 98.8
3 8.5 8.3 2 (2.6%) 31.5 97.1
4 11.6 11.1 3 (10.3%) 36.1 97.2
5 15.7 14.8 19 (19.2%) 37.7 96.3
6 20.8 19.4 11 (23.4%) 43 91.8
7 27 25 16 (27.6%) 46 89.9
8 34.3 31.5 21 (35%) 50.4 87.6
9 42.5 39 17 (48.6%) 55.4 85
10 51 46.9 18 (41.9%) 57 82.8
11 59.5 55 17 (50%) 63.2 81
12 67.5 62.9 13 (61.9%) 69.4 79.3
13 74.6 70.1 8 (50%) 72.5 77.9
14 80.5 76.5 11 (78.6%) 82.9 77.2
15 85.4 81.8 10 (83.3%) 85.7 76
16+ 89.2 86.2 8 (88.9%) 88.9 75
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International Myeloma Foundation with a curative strat-
egy is using the same model.
While we used 2-year progression as the end point to
define a high-risk SMM population, we have also created
a more precise and individualized scoring tool to classify
individuals by risk of progression using the entire spec-
trum of values for each patient (in place of dichotomous
division) including M-spike, BMPC infiltration, and sFLC
ratio. Accordingly, this scoring tool is able to precisely
identify SMM patients with extremely low risk of pro-
gression at 2 years (close to MGUS), as well as SMM with
a risk of progression at 2 years even >50%. Thus, using
this risk scoring, SMM patients with total risk score of 1
have 90% of probability of not developing MM in 2 years
(negative predictive value (NPV)= 90%), while for those
patients with total risk score of 9, the probability of
developing MM in 2 years will be of 93% (positive pre-
dictive value= 93%). However, the identification of SMM
patients who will not progress with near certainty (100%
NPV) is difficult, and in the subgroup of patients with
total risk score of 0, the risk does exist.
There are some limitations in this study because of its
retrospective nature as well as the missing data observed
for some variables that may have led to their exclusion in
the multistep process. This is the case for the presence of
immune paresis, percentage of plasma cells with aberrant
phenotype or circulating plasma cells, or the evolution of
the M-component and the decrease in hemoglobin. In
addition, differences in the specific methodology used for
FISH may vary from institution to institution. One addi-
tional limitation is its complete reliance on clinical fea-
tures. It has been recently shown that the mutational
landscape, particularly mutations in the RAS family as
well as c-Myc alterations, may independently predict
progression risk24. Moreover, the transition process from
SMM to MM could also involve growth of preexisting
clones due to a more permissive bone marrow micro-
environment25,26. The current study also does not factor
in other demographic factors such as race as the numbers
were insufficient to explore this.
In summary, our study identifies a subgroup of SMM
patients with 50% progression risk at 2 years from diag-
nosis based on the presence of two or three factors among
M-protein (>2 g/dL), BMPC infiltration (>20%), or the
ratio of involved versus uninvolved sFLC (>20). This
model is easily reproducible and available worldwide,
could be used to identify high-risk SMM patients in the
context of clinical research, and will contribute in the near
future to be able to offer early treatment to a more
homogeneous subgroup of SMM patients. Availability of
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Fig. 4 Risk of progression according to the risk score. Risk score was developed using the entire range of the values for BMPC, serum FLC, and
serum M-spike as well as cytogenetic abnormality. Patients with total risk score between 0 and 4 had a 2-year progression risk of 3.8%, patients with a
total score between 5 and 8 had a risk of 26%, those with a score between 9 and 12 had a risk of progression of 51%, and those with a score >12 had
a risk of progression of 73%.
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FISH data can improve the model and should be con-
sidered in all patients diagnosed with SMM. In addition,
development of a scoring system allows for more indivi-
dualized risk assessment. The trials going on and incor-
porating these features for the selection of the high-risk
SMM patients will contribute to validate the model and
ancillary biological studies can help to optimize it in the
future. Future studies should focus on incorporating other
tumor cell characteristics such as the presence of muta-
tions as well as alterations in the tumor microenviron-
ment, especially changes in the immune parameters.
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